IGC Pharma
6 hedge funds and large institutions have $363K invested in IGC Pharma in 2013 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
14% more capital invested
Capital invested by funds: $318K → $363K (+$45K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$29.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.9K |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$430 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Wells Fargo
San Francisco,
California
| $305K | – | – | – |
|
|
VKH
2
Virtu KCG Holdings
New York
| $33K | +$29.4K | +31,671 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $15K | +$13.9K | +14,956 | New |
|
4
Creative Planning
Overland Park,
Kansas
| $9K | – | – | – |
|
|
U
5
UBS
Zurich,
Switzerland
| $1K | +$430 | +464 | +85% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| – | +$6 | +7 | +100% |
|
IGC Hedge Fund Activity: Q4 2013 in Review
6 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2013, worth a combined $363K — up 14% from $318K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IGC positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $29.4K.
- 6 institutional investors held IGC Pharma (IGC) as of Q4 2013, up from 4 in Q3 2013.
- Funds reported $363K of IGC Pharma stock for Q4 2013, up 14% quarter-over-quarter.
- 2 funds opened new IGC Pharma positions in Q4 2013 and 0 closed out, a net change of +2 holders.
- The largest IGC Pharma buyer in Q4 2013 was Virtu KCG Holdings, an estimated $29.4K added.
Based on aggregated 13F filings for Q4 2013.